Who Paid My Doc
Julio Santory Ortiz
General Practice Las Piedras, PR Medical Doctor
NPI 1013979723 CMS profile 961759
Calle Inmaculada 103, Las Piedras, PR 00771
General payments
$1,258
Research payments
$0
Ownership & investment interest
$0
Through program year 2023, Julio Santory Ortiz of Las Piedras, PR is reported in the CMS Open Payments database as having received $1,258 across 31 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 83rd percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2023 | General | $131 | 4 | |
| 2022 | General | $195 | 4 | |
| 2021 | General | $73 | 3 | |
| 2020 | General | $289 | 10 | |
| 2019 | General | $570 | 10 |
Beside peers
- Julio Santory Ortiz
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Julio Santory Ortiz were reported at $0. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Julio Santory Ortiz | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $570 | $107 | $37–$285 | $163 |
| 2020 | $289 | $75 | $25–$213 | $114 |
| 2021 | $73 | $93 | $30–$272 | $132 |
| 2022 | $195 | $103 | $36–$279 | $149 |
| 2023 | $131 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $0 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 219 drugsPart D claims
24,518
Drug cost
$1,025,604
Branded share of claims
17.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 110 | $68,534 | |
| Farxiga Dapagliflozin Propanediol | Brand | 69 | $62,417 | |
| Janumet Xr Sitagliptin Phos/Metformin Hcl | Brand | 53 | $54,835 | |
| Jardiance Empagliflozin | Brand | 55 | $49,602 | |
| Trulicity Dulaglutide | Brand | 42 | $47,348 | |
| Synthroid Levothyroxine Sodium | Brand | 407 | $44,906 | |
| Xarelto Rivaroxaban | Brand | 45 | $42,087 | |
| Janumet Sitagliptin Phos/Metformin Hcl | Brand | 43 | $34,245 | |
| Tradjenta Linagliptin | Brand | 23 | $24,201 | |
| Jentadueto Xr Linagliptin/Metformin Hcl | Brand | 34 | $20,009 |
The 10 drugs with the highest cost, of 219 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 9 billing codesPaid by Medicare
$3,466
Medicare patients
27
Services billed
53
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Diabetes | 56% | |
| Chronic kidney disease | 41% | |
| Arthritis | 41% | |
| Osteoporosis | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
31 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other General Practice in Puerto Rico
Related records
General Practice in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.